A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with Refractory or Relapsed Acute Myeloid Leukemia (AML): CALGB 19902.

Richard M. Stone; Barry Kurt Moser; Philip Schulman; Robert Barrier; Jonathan E. Kolitz; Steven L. Allen; Wendy Stock; Ilene Galinsky; H. Jean Khoury; Richard A. Larson

doi:10.1182/blood.v104.11.873.873

A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with Refractory or Relapsed Acute Myeloid Leukemia (AML): CALGB 19902.

Identifier:nobleid.org/w1/20260515/799353CF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/799353CF.svg?ark=w1%2F20260515%2F799353CF)](https://nobleid.org/work/w1/20260515/799353CF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

A Dose Escalation and Phase II Study of Gemtuzumab Ozogamicin (GO) with High-Dose Cytarabine (HiDAC) for Patients (pts) with Refractory or Relapsed Acute Myeloid Leukemia (AML): CALGB 19902.

Identifier:nobleid.org/w1/20260515/799353CF

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/799353CF.svg?ark=w1%2F20260515%2F799353CF)](https://nobleid.org/work/w1/20260515/799353CF)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work